By Keith I. Block, MD
As you probably know, hormonal therapy is considered standard treatment for women – and men – with estrogen receptor-positive breast cancer, and tens of thousands of patients, predominantly women, receive this treatment each year. The most widely used option for premenopausal women—first introduced in the 1970s—is Tamoxifen, which blocks the activity of estrogen by binding to the hormone’s receptor site. In more recent years, for postmenopausal women, Tamoxifen has been upstaged by aromatase inhibitors (AIs), drugs that block production of estrogen. (AIs generally follow two years of Tamoxifen for premenopausal women.) Both AIs and Tamoxifen, used either separately or together in sequence comprise an essential conventional strategy for curbing the risk of breast cancer recurrence. And some recent data suggests that AIs may be more effective in preventing early relapses.